Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Total hip arthroplasty.
- Who it may be relevant to
- Registry conditions: Osteoarthritis, Hip, Rheumatoid Arthritis. Basic parameters: 18 years — 74 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Finland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Studies on the Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
Overview
The purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial omics.
Detailed description
The specific objectives of this project are:
1. Using the latest single-cell RNA sequencing (scRNAseq) techniques the investigators aim to A) characterize what kind of cell populations are found in different synovial tissues and blood derived samples of OA patients, B) determine how the cell composition differs between arthritic and corresponding non-arthritic tissues, C) map the transcriptional and regulatory landscape of the cells mentioned in A and B focusing on the inflammatory responses, D) determine what are the key molecular pathways activated in OA. 2. To determine if some of the blood-derived immune cell populations or their products could be used as biomarkers for OA. 3. To map the whole transcriptome and proteome of OA and non-arthritic control tissue while keeping the morphological context with spatial omics technologies. 4. Further differentiation and identification of OA endotypes utilizing the single-cell and spatial omics data.
The project includes a Rheumatoid sub-study where the main objective is to compare arthritic tissue and peripheral blood constituents between OA and rheumatoid arthritis patients to explore the differences in the disease mechanisms.
Interventions
- Procedure Total hip arthroplasty
Hip joint replacement surgery. Elective for RA and OA cases.
Primary outcome measures
- Characterization of cell populations in OA [Time frame: Starting during the first quarter of 2025, ending by the last quarter of 2026.]
- Comparison of cell populations between OA cases and controls [Time frame: Starting during the first quarter of 2025, ending by the last quarter of 2026.]
- Cellular landscape in OA [Time frame: Starting during the last quarter of 2024, ending by the last quarter of 2026.]
- Key molecular pathways of OA [Time frame: Starting during the last quarter of 2025, ending by the last quarter of 2027.]
- Comparison of disease mechanisms between RA and OA [Time frame: Starting during the last quarter of 2024, ending by the last quarter of 2028.]
Secondary outcome measures (2)
- Biomarkers for OA [Time frame: Starting during the second half of 2026, ending by the last quarter of 2028.]
- OA endotypes [Time frame: Starting during the first half of 2025, ending by the second half of 2027.]
Eligibility criteria
Inclusion Criteria for the main (OA) study:
Cases: Adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty.
Controls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty.
\----
Inclusion Criteria for the Rheumatoid sub-study:
Adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty.
\----
Exclusion criteria
- The body mass index must be below 35
- Age < 18 or > 74
- The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome.
For the Rheumatoid sub-study, the exclusion criteria are the same as above except for the RA.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Finland · 4 centers
- PET-centre, University of Turku — Turku
- Turku Bioscience, University of Turku — Turku
- Turku University Hospital — Turku
- Helsinki University Hospital — Espoo
Publications
- Rydgren E, Kotilainen SK, Piipponen M, Lönnberg T, Mikkola L. COMPARISON OF TWO HIGH-RESOLUTION SPATIAL TRANSCRIPTOMICS TECHNOLOGIES TO STUDY SYNOVIAL IMMUNE INFILTRATION IN OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS Osteoarthritis and Cartilage, Volume 33, Issue 6, 2025, page 816. https://doi.org/10.1016/j.joca.2025.03.079
Identifiers
NCT: NCT05278520 · 2022OASEQ